Metabolic control of YAP and TAZ by the mevalonate pathway

By G. Sorrentino, N. Ruggeri, V. Specchia, M. Cordenonsi, M. Mano, S. Dupont, Andrea Manfrin, Eleonora Ingallina, R. Sommaggio, Silvano Piazza and 3 more. Nature Cell Biology, 2014

749 citations recorded by the source corpus.

Subfields: Biochemistry, Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7d809a34de7af125f9851512dc332a4093b12f1f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. K. Guan
2. S. Piccolo
3. Fa-Xing Yu
4. Bin Zhao
5. M. Cordenonsi
6. S. Dupont
7. Z. Meng
8. Duojia Pan

In Molecular Biology

1. K. Guan
2. S. Piccolo
3. Fa-Xing Yu
4. Bin Zhao
5. M. Cordenonsi
6. Duojia Pan
7. Z. Meng
8. S. Dupont

Citations in the corpus

• The biology of YAP/TAZ: hippo signaling and beyond. (2014, background): “(190) instead suggests that the Rho and cytoskeletal pathway can be formally distinguished, as Rho regulates YAP through phosphorylation, while the cytoskeleton is phosphorylation-independent (4).”
• Mutant p53 as a guardian of the cancer cell (2018, neutral): “2), which in turn promotes activation of the YAP/TAZ oncoproteins [43], as well as stabilization of mutp53 itself [19] (Fig.”
• The Hippo Signaling Pathway in Development and Disease (2019, background): “, 2015a); statins, which suppress YAP by inhibiting the mevalonate pathway required for membrane targeting of Rho GTPase, and other inhibitors targeting Rho GTPase or its effector ROCK (Sorrentino et al., 2014; Wang et al., 2014); phosphodiesterase inhibitors rolipram and ibudilast, which suppress Y”
• YAP/TAZ-Dependent Reprogramming of Colonic Epithelium Links ECM Remodeling to Tissue Regeneration (2018, background): “Importantly, inhibitors affecting signaling downstream of integrins via Rho kinase (C3 toxin; Mevastatin) and actin polymerization (Cytochalasin D) all significantly reduced growth in collagen type I (Figure S4E; Dupont et al., 2011; Sorrentino et al., 2014).”
• Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. (2015, positive): “Indeed, mevalonate metabolic pathway inhibitor statins can block membrane translocation of Rho GTPases and indirectly inhibit YAP/TAZ activity (Mi et al., 2015; Sorrentino et al., 2014; Wang et al., 2014).”
• The Hippo Pathway: Biology and Pathophysiology. (2019, background): “As expected, statin also strongly inhibits YAP/TAZ (131).”
• YAP/TAZ at the roots of cancer (2016, background): “…such as Statins and Bisphosphonates, and it is encouraging that in large epidemiological studies patients treated with Statins are less prone to develop tumors and that mevalonate inhibitors can oppose the growth of HNSCC cells in mice (Li et al., 2015d; Sorrentino et al., 2014; Wang et al., 2014).”